Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Assistance Publique Hôpitaux De Paris currently has 1 pending office action within the Medical Devices & Mechanical Engineering technology area. This single matter is being reviewed by 1 distinct examiner, OGLES, MATTHEW ERIC, in 1 distinct art unit. This indicates a very focused and singular point of interaction for the company's current patent prosecution. The progress of the 1 pending office action depends entirely on the feedback from this examiner.
With only 1 pending office action, the administrative complexity is minimal. OGLES, MATTHEW ERIC is the busiest examiner by default, holding a workload of 1 pending office action. The involvement of 1 distinct art unit means that there are no competing departmental policies to consider. Practitioners can focus their efforts on the specific requirements of OGLES, MATTHEW ERIC to advance the 1 pending office action. This streamlined arrangement in the Medical Devices & Mechanical Engineering field provides a clear and direct path for the company's current intellectual property interests.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §112 only | 2 (50%) |
| No statute on record | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FERNSTROM, KURT | 1 | 65.8% | +14.2% |
| WARD, PAUL V | 1 | 83.2% | -12.2% |
| GIBBS, TERRA C | 1 | 63.7% | +10.4% |
| SIMMONS, VALERIE MICHELLE | 1 | 27.7% | +47.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18838160 | AMILORIDE FOR USE IN THE TOPICAL TREATMENT OF SOMATOSENSORY IMPAIRMENTS | WARD, PAUL V | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17293602 | METHOD FOR DETERMINING ONE CONTENT IN PROTEIN AND ASSOCIATED DEVICES AND METHODS | SIMMONS, VALERIE MICHELLE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18305809 | METHODS FOR PERFORMING ANTISENSE OLIGONUCLEOTIDE-MEDIATED EXON SKIPPING IN THE RETINA OF A SUBJECT IN NEED THEREOF | GIBBS, TERRA C | 121d overdue |
| 19189533 | ORGAN PERFUSION DEVICE | FERNSTROM, KURT | — |
| 17293602 | METHOD FOR DETERMINING ONE CONTENT IN PROTEIN AND ASSOCIATED DEVICES AND METHODS | SIMMONS, VALERIE MICHELLE | — |
| Art Unit | Apps |
|---|---|
| 3715 | 1 |
| 1622 | 1 |
| 1635 | 1 |
| 1758 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19189533 | ORGAN PERFUSION DEVICE | FERNSTROM, KURT | 3715 | Other | Non-Final OA | — | Pending | Apr 25, 2025 |
| 18838160 | AMILORIDE FOR USE IN THE TOPICAL TREATMENT OF SOMATOSENSORY IMPAIRMENTS | WARD, PAUL V | 1622 | §112 | Non-Final OA | — | Pending | Aug 13, 2024 |
| 18305809 | METHODS FOR PERFORMING ANTISENSE OLIGONUCLEOTIDE-MEDIATED EXON SKIPPING IN THE RETINA OF A SUBJECT IN NEED THEREOF | GIBBS, TERRA C | 1635 | §112 | Final Rejection | 121d overdue | Pending | Apr 24, 2023 |
| 17293602 | METHOD FOR DETERMINING ONE CONTENT IN PROTEIN AND ASSOCIATED DEVICES AND METHODS | SIMMONS, VALERIE MICHELLE | 1758 | §101§103§112 | Non-Final OA | — | Pending | May 13, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAssistance Publique - Hôpitaux de Paris has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Kurt Fernstrom has the most, with 1 of Assistance Publique - Hôpitaux de Paris's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
